Replies to post #433294 on Anavex Life Sciences Corp (AVXL)

[avxllent]

Brand NEW US patent application! Awesome George!

Thank you! I really appreciate your due diligence on these patents that you seem to find before anyone else.
The only thing I wish you would stop are the predictions. There is much going on behind the scenes with Anavex!

[falconer66a]

New Anavex Drug Patent — What else?

Well, Anavex filed for a new patent; to treat the seizures of epilepsy. How could this have happened?

Only by actually conducting experiments and studies of murines (lab rodents) utilizing Anavex’s proprietary molecules A19-144 and A2-73 (also known as blarcamesine).

Understand, Anavex simply is not revealing what the company is actually working on, with new molecules or new applications and indications for those molecules. All sorts of innovative experimentation going on at Anavex. Because of these closed-door studies, Anavex knows the deep extent and broad range of results their new drugs will yield in new therapies; for a widening diversity of indications.

In five years, the Anavex story will not be only blarcamesine for Rett and Alzheimer’s. Lots, lots more....

[tredenwater2]

New Patent????? What a complete distraction from the can kicker! (Sarc)

[Investor2014]

Essentially this tells us that neither A2-73 or A19-144 are effective on their own as anti-epilepsy drugs, despite Dr. DADO's investment thesis that A2-73 would be the next brilliant AED.

Of course PowerWalker will not like points [0108 - 01113] and claims 12 - 18. as these further goes towards ruining the Anti Donepezil Super Responder Theory (ASPT) and of course the idea that Donepezil as a high affinity S1R agonist competes with and excludes binding of e.g. A2-73.

[Bourbon_on_my_cornflakes]

Patent app - who is Cameron Durrant?
Dr. Cameron Durrant is the Chairman and Chief Executive Officer of Humanigen, since March 1, 2016. He was elevated to that position after serving on the board of directors starting January 7, 2016. Dr. Durrant’s expertise and business career has revolved around transformations, whether for brands, business units, or small companies. He has particular therapeutic experience in infectious diseases, pediatrics and oncology – coupled with experience as a practicing physician. He has served as board chairman, lead independent director and as CEO for several specialty pharma or biotech companies in both the private and public sector. He has been involved in several exits and has raised significant funding from a variety of sources. He is currently a founding director of a private nanotech oncology company, Bexion Pharmaceuticals, a board member of Immune Pharmaceuticals, a publicly traded immune-oncology biotech, and on the board of two private medical device companies. Dr. Durrant is also founder of the start-up Taran Pharma Limited, a private, semi-virtual specialty pharma company developing and registering treatments in Europe for orphan conditions Previously, Dr. Durrant was president and CEO of ECR Pharmaceuticals and a corporate officer of Hi-Tech Pharmacal; and the founder, Chairman, CEO and CFO of PediatRx, Inc., which marketed therapies for pediatric care, orphan conditions and oncology supportive care. His career has been built on extensive experience – including commercial, P&L, US and global responsibilities – as an operating executive at blue-chip pharmaceutical companies. Dr. Durrant has been President and CEO of PediaMed Pharmaceuticals, a company focused on bring important medicines to children in the US; and held senior executive positions at Johnson & Johnson and Pharmacia. He also had earlier roles at GlaxoSmithKline and Merck. He is a prior regional winner of the Ernst and Young ‘Entrepreneur of the Year’ award. Dr. Durrant earned his MD from the Welsh National School of Medicine, Cardiff, UK, his DRCOG from the Royal College of Obstetricians and Gynecologists, London, UK, and his MRCGP from the Royal College of General Practitioners, London, UK. He practiced medicine for eight years in the UK and Australia. He also earned his MBA from Henley Management College, Oxford, UK.
Per Linked In
Johnson & Johnson
16 yrs 9 mos
Worldwide Vice President
CEOCEO
SphericsSpherics
2006 - 2007 · 1 yr
CEO
PediaMed
2002 - 2006 · 4 yrs
Global VP, Infectious Diseases
Pharmacia
1999 - 2001 · 2 yrs
Per Yahoo Finance:
Dr. Cameron Durrant M.D., MBA Chairman, CEO & Acting CFO